Oncolytic Adenovirus TILT-123 Combined With TIL Therapy Is Safe in Metastatic Melanoma
Source: OncLive, January 2024
Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte (TIL) therapy in patients with advanced, metastatic melanoma, according to data from a phase 1 trial (NCT04217473) presented at the 2023 ESMO Immuno-Oncology Annual Congress.
Treatment with the oncolytic adenovirus in combination with TIL therapy resulted in 3 grade 3/4 adverse effects (AEs) related to TILT-123 and 5 related to TIL therapy, though no AEs were considered dose-limiting; however, 4 serious AEs were related to TILT-123, including fever (n = 3) and infection in the injected tumor (n = 1).
Notably, the disease control rate was 38% (n = 16). Of the evaluated patients, 62.5% had progressive disease, 25% had stable disease (SD), 6.3% had partial response (PR), and 6.3% had complete response (CR).